Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
0(0%)
Results Posted
31%(4 trials)
Terminated
3(13%)

Phase Distribution

Ph phase_2
3
13%
Ph phase_3
6
26%
Ph phase_4
10
43%
Ph phase_1
4
17%

Phase Distribution

4

Early Stage

3

Mid Stage

16

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
4(17.4%)
Phase 2Efficacy & side effects
3(13.0%)
Phase 3Large-scale testing
6(26.1%)
Phase 4Post-market surveillance
10(43.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

0

trials recruiting

Total Trials

23

all time

Status Distribution
Completed(13)
Terminated(5)
Other(5)

Detailed Status

Completed13
unknown5
Terminated3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
23
Active
0
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (17.4%)
Phase 23 (13.0%)
Phase 36 (26.1%)
Phase 410 (43.5%)

Trials by Status

withdrawn29%
unknown522%
completed1357%
terminated313%

Recent Activity

0 active trials
Showing 5 of 23
completedphase_4

Drug Transporter Interaction Study PHENTRA_2015_KPUK

NCT02743260
completedphase_1

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

NCT03801759
completedphase_4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

NCT00922207
completedphase_4

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

NCT01086085
unknownphase_4

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

NCT02482272
View all 23 trials

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT02743260Phase 4

Drug Transporter Interaction Study PHENTRA_2015_KPUK

Completed
NCT03801759Phase 1

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Completed
NCT00922207Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Completed
NCT01086085Phase 4

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Completed
NCT02482272Phase 4

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

Unknown
NCT02560649Phase 4

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Unknown
NCT00986778Phase 4

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

Withdrawn
NCT00409019Phase 4

Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy

Withdrawn
NCT02366208Phase 2

Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B

Completed
NCT02366247Phase 3

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B

Unknown
NCT01023217Phase 4

Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir

Completed
NCT00410202Phase 3

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

Completed
NCT01192854Phase 3

An Study of Efficacy and Safety of Clevudine

Completed
NCT01799486Phase 4

Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

Unknown
NCT00513968Phase 1

Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

Completed
NCT00798460Phase 4

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Terminated
NCT00096785Phase 3

Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

Completed
NCT00960518Phase 2

TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)

Unknown
NCT00496002Phase 3

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Terminated
NCT00496158Phase 3

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
23